Novartis Ag

Novartis Pharma Gmbh

Erik Meredith

Nan Ji

James J Powers

Nello Mainolfi

Chang Rao

Donglei Liu

Christopher Michael Adams

Fupeng Ma

Karl Miranda

Gerald David Artman, Iii

Jason Matthew Elliott

Gary Michael Ksander

Qi-Ying Hu

Muneto Mogi

Julien Papillon

Lauren Gilchrist Monovich

Mitsunori Kato

Takeru Ehara

Fariborz Firooznia

Michael H Serrano-Wu

Christine Fang Gelin

Toshio Kawanami

Rajeshri Ganesh Karki

Alec Nathanson Flyer

Catherine Fooks Solovay

Gang Liu

Keith Jendza

Taeyoung Yoon

Rajesh Karki

Christoph Gaul

Atwood Kim Cheung

Maurice Van Eis

Timothy Brian Hurley

Christoph Schumacher

Rui Zheng

Ritesh Bhanudasji Tichkule

Anette Von Matt

Vivek Rauniyar

Bin Hu

Doug Bevan

Luciana Ferrara

Ganesh Prasanna

Michael Paul Capparelli

David B Belanger

Philippe Bolduc

Veronique Darsigny

Chun Zhang

Daniela Angst

Justin Yik Ching Mao

Shuangxi Wang

Denis Har

Liansheng Su

Liang Zhao

Mitchell Brigell

Xinglong Jiang

George Tien-San Lee

Xiang Gao

Véronique Darsigny

Jeffrey M McKENNA

Matthew William Carson

Ajay Kumar Lal

Lichun Shen

Markus Rolf Dobler

Christopher Towler

Yubin Qiu

Peter End

Viktor Hornak

Gerald David Artman

David Belanger

Christina Cappaci-Daniel

Gerald David Artman Iii

Ronald Newton

Bruce Jaffee

Vinayak Hosagrahara

Jr Charles Francis Jewell

Stephen Poor

Sarah Siska

The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Rto R, and Rto R, are as described herein, as well as compositions and methods of using such compounds.

Hydroquinazoline derivatives for the treatment of a disease or disorder

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators

Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators

The present invention relates to a method of treating a disease or disorder characterized by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or &#x2014;C(O)N(R)(R) wherein Rand Rare independently &#x2014;(C-C) alkyl, or &#x2014;(C-C) alkyl-(C-C) aryl, wherein each of Rand Ris optionally substituted by &#x2014;(C-C) alkoxy; R, R, and R, are independently hydrogen, halogen, cyano or &#x2014;(C-C) aryl, wherein said &#x2014;(C-C) aryl is optionally substituted by halogen, with the proviso that no more than one of R, R, and Ris hydrogen; and Rand Rare hydrogen; or a pharmaceutically acceptable salt thereof. 

Use of an adrenal hormone-modifying agent

The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

Organic compounds

The present invention provides a compound of formula I: (I)a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

The present invention provides a compound of formula I:  Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or &#x2014;C(O)N(R)(R) wherein Rand Rare independently &#x2014;(C-C)alkyl, or &#x2014;(C-C)alkyl-(C-C)aryl, wherein each of Rand Ris optionally substituted by &#x2014;(C-C)alkoxy; R, R, and R, are independently hydrogen, halogen, cyano or &#x2014;(C-C) aryl, wherein said &#x2014;(C-C)aryl is optionally substituted by halogen, with the proviso that no more than one of R, R, and Ris hydrogen; and Rand Rare hydrogen; or a pharmaceutically acceptable salt thereof.

The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

Heterobicyclic carboxamides as inhibitors for kinases

The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.

Growing community of inventors

Hudson, MA, United States of America

Erik Meredith